Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CytoDyn ( (CYDY) ) has shared an update.
CytoDyn announced the appointment of Robert E. Hoffman as Chief Financial Officer, effective May 15, 2025, succeeding Mitch Cohen, who served as interim CFO. Hoffman’s extensive experience in the biotech sector is expected to bolster CytoDyn’s financial strategy and support its clinical development pipeline, particularly in oncology.
More about CytoDyn
CytoDyn is a clinical-stage biotechnology company focused on developing and commercializing leronlimab, a humanized monoclonal antibody targeting the CCR5 receptor, which is implicated in various disease processes. The company is exploring leronlimab’s potential in treating infectious diseases, oncology, and autoimmune conditions.
Average Trading Volume: 2,960,191
Technical Sentiment Signal: Buy
Current Market Cap: $400.4M
For a thorough assessment of CYDY stock, go to TipRanks’ Stock Analysis page.